Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 66
- Registration Number
- NCT00800436
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: RO4998452Drug: Placebo
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 394
- Registration Number
- NCT00800176
A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 372
- Registration Number
- NCT00800748
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT00800202
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT00796107
A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Radiation: Standard radiotherapyDrug: Capecitabine [Xeloda]
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT00796718
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Phase 2
Completed
- Conditions
- Renal Cell Cancer
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 146
- Registration Number
- NCT00796757
CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 136
- Registration Number
- NCT00788567
Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection
Phase 1
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: ANA598 200 mg bid or placeboDrug: ANA598 400 mg bid or placeboDrug: ANA598 800 mg bid or placebo
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT00782353
- Locations
- 🇺🇸
United States, Missouri, St. Louis, Missouri, United States
🇺🇸United States, New York, New York, New York, United States
🇵🇷Puerto Rico, Santurce, Santurce, Puerto Rico
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT00778102
© Copyright 2025. All Rights Reserved by MedPath